<DOC>
	<DOCNO>NCT00763529</DOCNO>
	<brief_summary>This open-label , randomize , parallel-group clinical study . The primary objective ass difference response rate mometasone furoate cream 0.1 % ( daily ) v fluticasone propionate cream 0.05 % ( twice daily ) end Day 4 Day 8 management Indian patient localize psoriasis .</brief_summary>
	<brief_title>Elocon v Fluticasone Localized Psoriasis ( P03197 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>&gt; =18 year age Written inform consent Having localize psoriasis ( 56 patch ) Total size patch 8 '' x 8 '' Each patient exhibit follow 4 sign dermatosis : erythema palpability scale itching ( pruritus ) Each sign would grade accord follow scale : 0 = none 1 . = slight 2 . = moderate 3 . = severe The total Disease Severity Score ( ie , sum score sign ) least 6 ( indicative moderate severe disease status ) Pregnancy lactation Hypersensitivity components test medication Signs atrophy target area Lesions palm , sol , scalp Individuals may require medication might affect natural course disease Not use systemic corticosteroid antimetabolites topical corticosteroid within 2 week prior enrollment study Concomitant tuberculosis/viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>